WallStreetZenWallStreetZen

NASDAQ: AVTE
Aerovate Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for AVTE

Based on 2 analysts offering 12 month price targets for Aerovate Therapeutics Inc.
Min Forecast
$35.00+62.26%
Avg Forecast
$50.00+131.8%
Max Forecast
$65.00+201.34%

Should I buy or sell AVTE stock?

Based on 2 analysts offering ratings for Aerovate Therapeutics Inc.
Strong Buy
Strong Buy
2 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their AVTE stock forecasts and price targets.

AVTE stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-04-01
lockedlocked$00.00+00.00%2024-03-25

1 of 1

Forecast return on equity

Is AVTE forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
35.16%

Forecast return on assets

Is AVTE forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

AVTE revenue forecast

What is AVTE's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$40.7M
Avg 2 year Forecast
$66.0M
Avg 3 year Forecast
$256.5M

AVTE vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
AVTE$21.57$50.00+131.80%Strong Buy
HLVX$12.02$30.67+155.13%Strong Buy
NRIX$12.36$21.33+72.60%Buy
CABA$12.18$34.33+181.88%Strong Buy
SVRA$4.45$9.25+107.87%Strong Buy
View Top Biotech Stocks

Aerovate Therapeutics Stock Forecast FAQ

Is Aerovate Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: AVTE) stock is to Strong Buy AVTE stock.

Out of 2 analysts, 2 (100%) are recommending AVTE as a Strong Buy, 0 (0%) are recommending AVTE as a Buy, 0 (0%) are recommending AVTE as a Hold, 0 (0%) are recommending AVTE as a Sell, and 0 (0%) are recommending AVTE as a Strong Sell.

If you're new to stock investing, here's how to buy Aerovate Therapeutics stock.

What is AVTE's revenue growth forecast for 2026-2028?

(NASDAQ: AVTE) Aerovate Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.04%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.92%.

Aerovate Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast AVTE's revenue for 2026 to be $1,134,858,402, with the lowest AVTE revenue forecast at $1,134,858,402, and the highest AVTE revenue forecast at $1,134,858,402. On average, 1 Wall Street analysts forecast AVTE's revenue for 2027 to be $1,838,119,537, with the lowest AVTE revenue forecast at $1,838,119,537, and the highest AVTE revenue forecast at $1,838,119,537.

In 2028, AVTE is forecast to generate $7,146,849,497 in revenue, with the lowest revenue forecast at $7,146,849,497 and the highest revenue forecast at $7,146,849,497.

What is AVTE's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: AVTE) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is AVTE's Price Target?

According to 2 Wall Street analysts that have issued a 1 year AVTE price target, the average AVTE price target is $50.00, with the highest AVTE stock price forecast at $65.00 and the lowest AVTE stock price forecast at $35.00.

On average, Wall Street analysts predict that Aerovate Therapeutics's share price could reach $50.00 by Apr 1, 2025. The average Aerovate Therapeutics stock price prediction forecasts a potential upside of 131.8% from the current AVTE share price of $21.57.

What is AVTE's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: AVTE) forecast ROE is N/A, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.